Similar Search Results

Consumer decision making from a beloved brand : the Aspirin case

Borges, Ana Pinto; Rodrigues, Paula Cristina Lopes - In: New techniques for brand management in the healthcare sector, (pp. 184-198). 2021

Persistent link: https://www.econbiz.de/10012516044

Do Pharmacists Buy Bayer? Informed Shoppers and the Brand Premium

Bronnenberg, Bart J. - 2014

suggest that misinformation and related consumer mistakes explain a sizable share of the brand premium for health products …

Persistent link: https://www.econbiz.de/10012458372

A new approach to estimating state dependence in consumers' brand choices applied to 762 pharmaceutical markets

Granlund, David - 2019

Persistent link: https://www.econbiz.de/10012193424

Measuring customer-based brand equity in traditional herbal medicine market in Kumasi, Ghana

Oppong, Peter Kwasi; Phiri, Maxwell A. - In: African journal of business and economic research : AJBER 13 (2018) 3, pp. 115-133

Persistent link: https://www.econbiz.de/10012055987

Forecasting branded and generic pharmaceuticals

Nikolopoulos, Konstantinos; Buxton, Samantha; Khammash, … - In: International journal of forecasting 32 (2016) 2, pp. 344-357

Persistent link: https://www.econbiz.de/10011596831

Branded vs. generic drugs : the role of self-perceived seriousness of disease

Sestino, Andrea; Amatulli, Cesare - In: International journal of pharmaceutical and healthcare … 16 (2022) 1, pp. 22-39

Persistent link: https://www.econbiz.de/10012886098

Trademarks As Sources of Market Power : Drugs, Beers and Product Differentiation

Morris, P. Sean - 2017

hopping in pharmaceuticals. I then develop a theory of branded monopoly and suggest that there is a need for a new direction …

Persistent link: https://www.econbiz.de/10012967595

Do pharmacists buy Bayer? : informed shoppers and the brand premium

Bronnenberg, Bart J.; Dubé, Jean-Pierre; Gentzkow, … - In: The quarterly journal of economics 130 (2015) 4, pp. 1669-1726

Persistent link: https://www.econbiz.de/10011457870

The Stay Dilemma : Examining Brand and Generic Incentives for Delaying the Resolution of Pharmaceutical Patent Litigation

Herman, Michael R. - 2014

The Hatch-Waxman Act encourages generic drug companies to challenge the patents on brand name drugs by awarding the … patent usually triggers patent infringement litigation from the brand name firm. In response to the increased numbers of … patent challenges, brand name firms have adopted an “evergreening” strategy — filing for multiple patents for each drug …

Persistent link: https://www.econbiz.de/10014172696

Competition between generic and brand name drugs : new evidence from the U.S. pharmaceutical market

Cavaliere, Alberto; Moayedizadeh, Ashin - 2022

Persistent link: https://www.econbiz.de/10014232582